SG11202006296YA - Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors - Google Patents
Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitorsInfo
- Publication number
- SG11202006296YA SG11202006296YA SG11202006296YA SG11202006296YA SG11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA SG 11202006296Y A SG11202006296Y A SG 11202006296YA
- Authority
- SG
- Singapore
- Prior art keywords
- dihydrobenzofuran
- inden
- analogs
- cardiac sarcomere
- inhibitors
- Prior art date
Links
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 title 2
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical class C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 title 1
- 230000000747 cardiac effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 210000002235 sarcomere Anatomy 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
- C07F5/02—Boron compounds
- C07F5/027—Organoboranes and organoborohydrides
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862619643P | 2018-01-19 | 2018-01-19 | |
| US201862745724P | 2018-10-15 | 2018-10-15 | |
| PCT/US2019/014344 WO2019144041A1 (en) | 2018-01-19 | 2019-01-18 | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202006296YA true SG11202006296YA (en) | 2020-08-28 |
Family
ID=65324663
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202006296YA SG11202006296YA (en) | 2018-01-19 | 2019-01-18 | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US10836755B2 (en) |
| EP (1) | EP3740481A1 (en) |
| JP (2) | JP7401439B2 (en) |
| KR (1) | KR20200112895A (en) |
| CN (1) | CN111757875B (en) |
| AU (1) | AU2019208331A1 (en) |
| BR (1) | BR112020014428A2 (en) |
| CA (1) | CA3087283A1 (en) |
| CL (2) | CL2020001871A1 (en) |
| CO (1) | CO2020009225A2 (en) |
| EC (1) | ECSP20044709A (en) |
| IL (1) | IL276094B2 (en) |
| MA (1) | MA51620A (en) |
| MX (2) | MX2020007532A (en) |
| PH (1) | PH12020551090A1 (en) |
| SG (1) | SG11202006296YA (en) |
| UY (1) | UY38057A (en) |
| WO (1) | WO2019144041A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019208331A1 (en) | 2018-01-19 | 2020-07-16 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| US11964967B2 (en) * | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US20210276991A1 (en) * | 2018-06-26 | 2021-09-09 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| CN112867539A (en) | 2018-08-31 | 2021-05-28 | 赛特凯恩蒂克公司 | Cardiac muscle segment inhibitor |
| WO2020227097A1 (en) * | 2019-05-03 | 2020-11-12 | Praxis Precision Medicines, Inc. | Kcnt1 inhibitors and methods of use |
| BR112022000494A2 (en) * | 2019-07-17 | 2022-03-03 | Cytokinetics Inc | Polymorph, methods for making polymorph, for treating heart disease, for treating a disease or condition, and for inhibiting the cardiac sarcomere, and, pharmaceutical composition |
| AU2020315433A1 (en) * | 2019-07-17 | 2022-03-03 | Cytokinetics, Inc. | Polymorphs of (R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazole-5-carboxamide |
| US20220265612A1 (en) * | 2019-07-17 | 2022-08-25 | Cytokinetics, Inc. | Cardiac sarcomere inhibitor oral formulations |
| CN112094253B (en) * | 2020-09-10 | 2023-01-10 | 株式会社大熊制药 | Synthetic method for preparing SGLT inhibitor intermediate |
| US11919909B2 (en) | 2021-03-04 | 2024-03-05 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| TW202320763A (en) * | 2021-07-16 | 2023-06-01 | 美商胞質動力學公司 | Methods for treating hypertrophic cardiomyopathy |
| IL310592A (en) | 2021-08-03 | 2024-04-01 | Cytokinetics Inc | Process for preparing aficamten |
| WO2023211872A1 (en) | 2022-04-26 | 2023-11-02 | MyoKardia, Inc. | Methods of administering myosin inhibitors |
| US20240091203A1 (en) | 2022-07-20 | 2024-03-21 | Cytokinetics, Incorporated | Methods for treating non-obstructive hypertrophic cardiomyopathy |
| WO2024031016A1 (en) | 2022-08-04 | 2024-02-08 | Cytokinetics, Incorporated | Methods for treating obstructive hypertrophic cardiomyopathy |
| WO2024040190A1 (en) | 2022-08-18 | 2024-02-22 | Cytokinetics, Incorporated | Indane and coumaran derivatives as fast skeletal muscle myosin inhibitors |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US633499A (en) | 1899-06-29 | 1899-09-19 | Oil Well Supply Co | Coupling for pipes, tubes, or casings. |
| US6334997B1 (en) * | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| ATE372966T1 (en) | 1994-03-25 | 2007-09-15 | Isotechnika Inc | IMPROVED EFFECTIVENESS OF DRUGS THROUGH DEUTERATION |
| US5919785A (en) | 1996-04-03 | 1999-07-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO2003059265A2 (en) | 2001-12-21 | 2003-07-24 | Cytokinetics, Inc. | Compositions and methods for treating heart failure |
| US7399866B2 (en) * | 2003-01-14 | 2008-07-15 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| ATE524452T1 (en) | 2003-03-27 | 2011-09-15 | Cytokinetics Inc | SULFONAMIDES FOR TREATING CONGESTIVE HEART FAILURE, COMPOSITIONS AND USES THEREOF. |
| ATE388708T1 (en) | 2003-06-20 | 2008-03-15 | Amgen Inc | PIPERAZINE DERIVATIVES AND METHODS OF USE |
| DK1765327T3 (en) * | 2004-06-17 | 2014-11-03 | Cytokinetics Inc | Compounds, Compositions and Methods |
| US20060173183A1 (en) * | 2004-12-31 | 2006-08-03 | Alantos Pharmaceuticals, Inc., | Multicyclic bis-amide MMP inhibitors |
| GT200600164A (en) | 2005-04-22 | 2007-03-14 | DERIVATIVES OF DIHYDROBENZOFURANS AND USES OF THE SAME | |
| EP1959962A2 (en) | 2005-12-16 | 2008-08-27 | Cytokinetics, Inc. | Certain chemical entities, compositions, and methods |
| RU2318818C1 (en) | 2006-04-12 | 2008-03-10 | Общество С Ограниченной Ответственностью "Исследовательский Институт Химического Разнообразия" | Azaheterocycles, combinatory library, focused library, pharmaceutical composition and method for preparing (variants) |
| SA08290245B1 (en) | 2007-04-23 | 2012-02-12 | استرازينيكا ايه بي | Novel n- (8-Heteroaryltetrahydronaphtalene-2-Y1) or N- (5- Heteroarylchromane-3-Y1) Carboxamide Derivatives for the Treatment of Pain |
| US20090192168A1 (en) | 2008-01-04 | 2009-07-30 | Alex Muci | Compounds, Compositions and Methods |
| US20110275673A1 (en) | 2008-09-19 | 2011-11-10 | Yibin Xiang | Inhibitors of sphingosine kinase 1 |
| AU2010247414B2 (en) | 2009-05-15 | 2013-08-01 | Novartis Ag | Aryl pyridine as aldosterone synthase inhibitors |
| US8592426B2 (en) | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP2804865B1 (en) | 2012-01-20 | 2015-12-23 | Actelion Pharmaceuticals Ltd. | Heterocyclic amide derivatives as p2x7 receptor antagonists |
| US9199945B2 (en) | 2013-06-21 | 2015-12-01 | MyoKardia, Inc. | Cycloalkyl-substituted pyrimidinedione compounds |
| BR112015031864B1 (en) | 2013-06-21 | 2022-02-15 | Myokardia, Inc | PYRIMIDINEDIONE COMPOUNDS AGAINST HEART CONDITIONS, PHARMACEUTICAL COMPOSITION AND USE |
| US9663516B2 (en) | 2014-12-18 | 2017-05-30 | MyoKardia, Inc. | Bicyclic-pyrimidinedione compounds |
| HRP20230737T1 (en) | 2015-01-22 | 2023-10-13 | MyoKardia, Inc. | 4-methylsulfonyl-substituted piperidine urea compounds useful for the treatment of cardiac disorders such as dilated cardiomyopathy (dcm) |
| EP3390397A1 (en) | 2015-12-17 | 2018-10-24 | Syngenta Participations AG | Microbiocidal oxadiazole derivatives |
| US20190364899A1 (en) | 2015-12-18 | 2019-12-05 | Syngenta Participations Ag | Microbiocidal oxadiazole derivatives |
| AU2017257151A1 (en) | 2016-04-29 | 2018-11-15 | Board Of Regents, The University Of Texas System | Sigma receptor binders |
| EP3475275B1 (en) | 2016-06-23 | 2024-04-10 | Merck Sharp & Dohme LLC | 3-aryl and heteroaryl substituted 5-trifluoromethyl oxadiazoles as histone deacetylase 6 (hdac6) inhibitors |
| PE20190609A1 (en) | 2016-09-27 | 2019-04-23 | Merck Sharp & Dohme | DERIVATIVES OF CHROMANO, ISOCROMANO AND DIHYDROISOBENZOFURANOS AS NEGATIVE ALLOSTERIC MODULATORS OF mGluR2, COMPOSITIONS AND ITS USE |
| WO2018089433A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL mTORC INHIBITORS AND USES THEREOF |
| WO2018156883A1 (en) | 2017-02-23 | 2018-08-30 | Board Of Regents, The University Of Texas System | Methods of treatment for cancer, sterol homeostasis, and neurological diseases |
| MX2020001406A (en) | 2017-08-04 | 2020-03-09 | Myokardia Inc | Mavacamten for use in the treatment of hypertrophic cardiomyopathy. |
| AU2019208331A1 (en) | 2018-01-19 | 2020-07-16 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| SG11202008560VA (en) | 2018-03-08 | 2020-10-29 | Incyte Corp | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| US20210276991A1 (en) | 2018-06-26 | 2021-09-09 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US11964967B2 (en) | 2018-06-26 | 2024-04-23 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| CN112867539A (en) | 2018-08-31 | 2021-05-28 | 赛特凯恩蒂克公司 | Cardiac muscle segment inhibitor |
| KR20230079053A (en) | 2020-08-28 | 2023-06-05 | 미요카디아, 인크. | Methods of treatment using myosin modulators |
-
2019
- 2019-01-18 AU AU2019208331A patent/AU2019208331A1/en active Pending
- 2019-01-18 WO PCT/US2019/014344 patent/WO2019144041A1/en unknown
- 2019-01-18 KR KR1020207023807A patent/KR20200112895A/en not_active Application Discontinuation
- 2019-01-18 JP JP2020539814A patent/JP7401439B2/en active Active
- 2019-01-18 UY UY38057A patent/UY38057A/en unknown
- 2019-01-18 CA CA3087283A patent/CA3087283A1/en active Pending
- 2019-01-18 MX MX2020007532A patent/MX2020007532A/en unknown
- 2019-01-18 SG SG11202006296YA patent/SG11202006296YA/en unknown
- 2019-01-18 MA MA051620A patent/MA51620A/en unknown
- 2019-01-18 CN CN201980009128.5A patent/CN111757875B/en active Active
- 2019-01-18 BR BR112020014428-2A patent/BR112020014428A2/en unknown
- 2019-01-18 EP EP19703917.5A patent/EP3740481A1/en active Pending
- 2019-01-18 US US16/252,483 patent/US10836755B2/en active Active
-
2020
- 2020-07-14 CL CL2020001871A patent/CL2020001871A1/en unknown
- 2020-07-14 MX MX2022014312A patent/MX2022014312A/en unknown
- 2020-07-16 IL IL276094A patent/IL276094B2/en unknown
- 2020-07-16 PH PH12020551090A patent/PH12020551090A1/en unknown
- 2020-07-27 CO CONC2020/0009225A patent/CO2020009225A2/en unknown
- 2020-07-31 EC ECSENADI202044709A patent/ECSP20044709A/en unknown
- 2020-09-04 US US17/013,472 patent/US11472796B2/en active Active
-
2022
- 2022-04-28 CL CL2022001091A patent/CL2022001091A1/en unknown
- 2022-08-31 US US17/823,910 patent/US20230119665A1/en active Pending
-
2023
- 2023-09-26 JP JP2023163639A patent/JP2023169374A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US10836755B2 (en) | 2020-11-17 |
| US20210147399A1 (en) | 2021-05-20 |
| CN111757875B (en) | 2024-01-09 |
| CO2020009225A2 (en) | 2020-08-10 |
| EP3740481A1 (en) | 2020-11-25 |
| AU2019208331A1 (en) | 2020-07-16 |
| US20230119665A1 (en) | 2023-04-20 |
| IL276094B2 (en) | 2023-08-01 |
| TW201940471A (en) | 2019-10-16 |
| UY38057A (en) | 2019-08-30 |
| MX2020007532A (en) | 2020-09-09 |
| CL2022001091A1 (en) | 2023-01-20 |
| JP7401439B2 (en) | 2023-12-19 |
| MX2022014312A (en) | 2022-12-07 |
| IL276094B1 (en) | 2023-04-01 |
| CL2020001871A1 (en) | 2020-10-23 |
| US11472796B2 (en) | 2022-10-18 |
| US20190256504A1 (en) | 2019-08-22 |
| JP2023169374A (en) | 2023-11-29 |
| MA51620A (en) | 2020-11-25 |
| PH12020551090A1 (en) | 2021-09-01 |
| CA3087283A1 (en) | 2019-07-25 |
| BR112020014428A2 (en) | 2020-12-01 |
| CN111757875A (en) | 2020-10-09 |
| JP2021511331A (en) | 2021-05-06 |
| WO2019144041A1 (en) | 2019-07-25 |
| KR20200112895A (en) | 2020-10-05 |
| ECSP20044709A (en) | 2020-10-30 |
| IL276094A (en) | 2020-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276094B1 (en) | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors | |
| IL283639A (en) | Kif18a inhibitors | |
| IL281075A (en) | Cardiac sarcomere inhibitors | |
| IL271028A (en) | Inhibition of crystal growth of roflumilast | |
| IL284508A (en) | Irreversible inhibitors of menin-mll interaction | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL281939A (en) | Inhibitors of vap-1 | |
| GB2570161B (en) | Simulation of exclusive instructions | |
| IL304110A (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| IL281815A (en) | Inhibitors of vap-1 | |
| IL276013A (en) | Pi4kiiibeta inhibitors | |
| GB201708457D0 (en) | Inhibitors of metallo-beta-lactamases | |
| EP3894768C0 (en) | Methods of cryo-curing | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| IL277806A (en) | Growth inhibitor | |
| ZA202105399B (en) | Use of spiropidion | |
| IL277578A (en) | Novel salt forms of urat-1 inhibitors | |
| SG11202107734TA (en) | Controlled tissue anchor spacing | |
| GB201819164D0 (en) | Artificial-intelligence-assisted surgery | |
| AU201714976S (en) | Slide-on anchor point | |
| IL291368A (en) | Inhibitor of metadherin expression | |
| PT3901141T (en) | Novel form of isoquinolinesulfonamide | |
| IL265948A (en) | Zigomatic surgical leads | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors |